Patents Assigned to Revivicor, Inc.
  • Publication number: 20230255185
    Abstract: The present invention provides transgenic animals (e.g., transgenic porcine animals), organs, tissues, and cells derived from the transgenic animals that are particularly useful for xenotransplantation therapies. In particular, the present invention provides transgenic porcine animals, as well as organs, tissues and cells derived from the transgenic porcine animals, which lack any expression of a functional alpha 1,3 galactosyltransferase (GTKO) gene and comprise at least six transgenes under the control of at least three promoters within a single multi-gene expression vector, and further comprise at least four additional genetic modifications. Also provided are methods of making the transgenic animals (e.g., transgenic porcine animals), and methods of using the transgenic animals, organs, tissues, and cells derived from the transgenic animals for xenotransplantation therapies and treating a disease or condition.
    Type: Application
    Filed: September 19, 2022
    Publication date: August 17, 2023
    Applicant: Revivicor, Inc.
    Inventors: Maria Kokkinaki, Kasinath V. Kuravi
  • Publication number: 20220257829
    Abstract: Disclosed are compositions derived from non-primate mammals having reduced expression of alpha 1,3 gal and their use in food products, food additives, cosmetic products, cosmetic additives, medical products, medical devices and products used in research and production of therapeutics. The compositions and methods disclosed are particularly useful to subjects diagnosed with ?-Gal Syndrome (AGS).
    Type: Application
    Filed: October 10, 2019
    Publication date: August 18, 2022
    Applicant: Revivicor, Inc.
    Inventors: John Bianchi, David Ayares, Anneke Walters, Amy Dandro
  • Publication number: 20220211018
    Abstract: The present disclosure is directed to transgenic animals (e.g., transgenic porcine animals) comprising multiple genetic modifications that advantageously render these animals suitable donors for xenotransplanation. The present disclosure extends to organs, organ fragments, tissues and cells derived from these animals and their therapeutic use. The present disclosure further extends to methods of making such animals. In certain embodiments, the transgenic animals (e.g., transgenic porcine animals) have reduced expression of the growth hormone receptor (GHR) gene or have impaired function of the GHR protein.
    Type: Application
    Filed: November 19, 2021
    Publication date: July 7, 2022
    Applicant: Revivicor, Inc.
    Inventors: Martine ROTHBLATT, David AYARES, Willard EYESTONE
  • Publication number: 20220072200
    Abstract: The present invention provides certain donor animals, tissues and cells that are particularly useful for xenotransplantation therapies. In particular, the invention includes porcine animals, as well as tissue and cells derived from these, which lack any expression of functional alpha 1,3 galactosyltransferase (aGT) and express one or more additional transgenes which make these animals suitable donors for xenotransplantation of vascularized xenografts and derivatives thereof. Methods of treatment and using organs, tissues and cells derived from such animals are also provided.
    Type: Application
    Filed: November 22, 2021
    Publication date: March 10, 2022
    Applicant: Revivicor, Inc.
    Inventor: David AYARES
  • Patent number: 11179496
    Abstract: The present invention provides certain donor animals, tissues and cells that are particularly useful for xenotransplantation therapies. In particular, the invention includes porcine animals, as well as tissue and cells derived from these, which lack any expression of functional alpha 1,3 galactosyltransferase (aGT) and express one or more additional transgenes which make these animals suitable donors for xenotransplantation of vascularized xenografts and derivatives thereof. Methods of treatment and using organs, tissues and cells derived from such animals are also provided.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: November 23, 2021
    Assignee: Revivicor, Inc.
    Inventor: David Ayares
  • Patent number: 11172658
    Abstract: The present invention is a porcine animal, tissue, organ, cells and cell lines, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha1,3GT). These animals, tissues, organs and cells can be used in xenotransplantation and for other medical purposes.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: November 16, 2021
    Assignee: Revivicor, Inc.
    Inventors: Carol J. Phelps, David L. Ayares
  • Patent number: 11085054
    Abstract: The present invention provides ungulate animals, tissue and organs as well as cells and cell lines derived from such animals, tissue and organs, which lack expression of functional endogenous immunoglobulin loci. The present invention also provides ungulate animals, tissue and organs as well as cells and cell lines derived from such animals, tissue and organs, which express xenogenous, such as human, immunoglobulin loci. The present invention further provides ungulate, such as porcine genomic DNA sequence of porcine heavy and light chain immunogobulins. Such animals, tissues, organs and cells can be used in research and medical therapy. In addition, methods are provided to prepare such animals, organs, tissues, and cells.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: August 10, 2021
    Assignee: Revivicor, Inc.
    Inventors: Kevin Wells, David Ayares
  • Patent number: 10912863
    Abstract: The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: February 9, 2021
    Assignee: Revivicor, Inc.
    Inventors: David Ayares, Paul Rohricht
  • Patent number: 10793873
    Abstract: The invention provides cells and animals, as well as methods of producing cells and animals, that express at least one interfering RNA molecule to regulate the expression of a specific gene or family of genes. The invention further provides novel iRNA molecules, as well as DNA templates for producing iRNA molecules.
    Type: Grant
    Filed: November 22, 2004
    Date of Patent: October 6, 2020
    Assignee: Revivicor, Inc.
    Inventor: Kevin Wells
  • Patent number: 10383317
    Abstract: The present invention provides certain animals, and in particular porcine animals, tissue and cells derived from these, which lack any expression of functional alpha 1,3 galactosyltransferase (aGT) and express one or more additional transgenes which make them suitable donors for pancreatic islet xenotransplantation. Methods of treatment and prevention of diabetes using cells derived from such animals are also provided.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: August 20, 2019
    Assignee: Revivicor, Inc.
    Inventor: David L. Ayares
  • Patent number: 10300112
    Abstract: The present invention provides ungulates, including pigs, expressing CTLA4-Ig, as well as tissue, organs, cells and cell lines derived from such animals. Such animals, tissues, organs and cells can be used in research and medical therapy, including xenotransplanation. In addition, methods are provided to prepare organs, tissues and cells expressing the CTLA4-Ig for use in xenotransplantation, and nucleic acid constructs and vectors useful therein.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: May 28, 2019
    Assignee: Revivicor, Inc.
    Inventor: David Lee Ayares
  • Patent number: 10149461
    Abstract: Porcine animals, tissue and organs as well as cells and cell lines derived from such animals are provided that lack functional endogenous immunoglobulin loci and are deficient in immunoglobulin expression and B-cells. These animals are useful as model systems for research and for development of new pharmaceutical and biological agents. In addition, methods are provided to prepare such animals.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: December 11, 2018
    Assignee: Revivicor, Inc.
    Inventors: David L. Ayares, Michael Mendicino, Kevin Wells, Amy S. Dandro
  • Patent number: 10130737
    Abstract: The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: November 20, 2018
    Assignee: Revivicor, Inc.
    Inventors: David Ayares, Paul Rohricht
  • Patent number: 9585374
    Abstract: The present invention provides ungulate animals, tissue and organs as well as cells and cell lines derived from such animals, tissue and organs, which lack expression of functional endogenous immunoglobulin loci. The present invention also provides ungulate animals, tissue and organs as well as cells and cell lines derived from such animals, tissue and organs, which express xenogenous, such as human, immunoglobulin loci. The present invention further provides ungulate, such as porcine genomic DNA sequence of porcine heavy and light chain immunogobulins. Such animals, tissues, organs and cells can be used in research and medical therapy. In addition, methods are provided to prepare such animals, organs, tissues, and cells.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: March 7, 2017
    Assignee: Revivicor, Inc.
    Inventors: Kevin Wells, David Ayares
  • Patent number: 9339519
    Abstract: The present invention provides certain animals, and in particular porcine animals, tissue and cells derived from these, which lack any expression of functional alpha 1,3 galactosyltransferase (?GT) and express one or more additional transgenes which make them suitable donors for pancreatic islet xenotransplantation. Methods of treatment and prevention of diabetes using cells derived from such animals are also provided.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: May 17, 2016
    Assignee: Revivicor, Inc.
    Inventor: David Ayares
  • Publication number: 20150182664
    Abstract: The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices.
    Type: Application
    Filed: August 1, 2014
    Publication date: July 2, 2015
    Applicant: Revivicor, Inc.
    Inventors: David Ayares, Paul Rohricht
  • Patent number: 8106251
    Abstract: The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices.
    Type: Grant
    Filed: March 17, 2005
    Date of Patent: January 31, 2012
    Assignee: Revivicor, Inc.
    Inventors: David Ayares, Paul Rohricht
  • Patent number: 7795493
    Abstract: The present invention is a porcine animal, tissue, organ, cells and cell lines, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha1,3GT). These animals, tissues, organs and cells can be used in xenotransplantation and for other medical purposes.
    Type: Grant
    Filed: August 21, 2003
    Date of Patent: September 14, 2010
    Assignee: Revivicor, Inc.
    Inventors: Carol J. Phelps, David L. Ayares
  • Publication number: 20060147432
    Abstract: It has been found that dendritic cells can be prepared which cannot mature. These cells can provide signal 1 to T cells but cannot provide co-stimulatory signal 2. T cells which are stimulated by the permanently immature dendritic cells therefore anergise, so the dendritic cells are tolerogenic rather than immunogenic. The cells are generally CD40?ve, CD80?ve and CD86?ve, and remain so when stimulated by inflammatory mediators such as lipopolysaccharide. The cells can be prepared conveniently by the culturing adherent embryonic stem cells in the presence of GM-CSF.
    Type: Application
    Filed: February 24, 2006
    Publication date: July 6, 2006
    Applicant: Revivicor, Inc.
    Inventors: Marilyn Moore, Andrew Leishman, Donald Innes
  • Publication number: 20050266561
    Abstract: The invention provides cells and animals, as well as methods of producing cells and animals, that express at least one interfering RNA molecule to regulate the expression of a specific gene or family of genes. The invention further provides novel iRNA molecules, as well as DNA templates for producing iRNA molecules.
    Type: Application
    Filed: November 22, 2004
    Publication date: December 1, 2005
    Applicant: Revivicor, Inc.
    Inventor: Kevin Wells